Skip to content
Screener

Insmed INSM Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Mannkind logo
MannkindMNKD
$257.25K—

Other financials

Income statement

See full
Revenue$425.5M+296%
Gross profit$358.3M+352%
Operating income-$1.5M+99.5%
Net income-$13.2M+95.9%
EPS (diluted)-$0.06+96.5%

Balance sheet

See full
Cash & equivalents$544.8M-57.6%
Total debt$579.9M+0.8%
Total equity$757.5M-39.4%
Total assets$2.1B-15.2%

Cash flow

See full
Operating cash flow-$88.8M+56.8%
CapEx$6.3M+79.6%
Free cash flow-$95.1M+54.5%

Valuation

See full
Market cap$28.63B+20.0%
Enterprise value$28.66B+23.8%
P/S25.2×-34.8×

Profitability

See full
Gross margin83.5%+7.7pp
Operating margin-73.9%-30.6pp
Net margin-76.9%-31.8pp
FCF margin-71%-28.6pp

Returns & leverage

See full
Return on equity-87.2%-27.3pp
Debt / equity0.8×+0.3×
Current ratio3.7×-3.0×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The source filing: Insmed’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104506-26-000041
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development210,034177,190419,519329,767
Selling, general and administrative247,467154,763494,726302,308
Amortization of intangible assets2,0811,2634,1622,526
Change in fair value of contingent consideration(99,760)59,000(146,721)77,300
Total operating expenses427,034420,291886,318761,254
Operating loss(1,548)(312,876)(154,868)(561,016)
Investment income10,97913,22523,01927,131
Interest expense(20,273)(21,245)(40,355)(42,814)

Item 1C. Consolidated Financial Statements

FAQ

What is Insmed's contingent consideration fair value adjustments?
Insmed (INSM) reported contingent consideration fair value adjustments of -$99.76M in Q2 2026.
How has Insmed's contingent consideration fair value adjustments changed year-over-year?
Insmed's contingent consideration fair value adjustments decreased by 269.1% year-over-year, from $59M to -$99.76M.
What is the long-term trend for Insmed's contingent consideration fair value adjustments?
Over 2 years (2022 to 2025), Insmed's contingent consideration fair value adjustments has grown at a 248.1% compound annual growth rate (CAGR), from -$20.8M to $251.99M.
What does contingent consideration fair value adjustments mean?
Contingent consideration fair value adjustments

Ask your AI about Insmed's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude